Kinesin family member 20B (KIF20B, also known as MPHOSPH1) is a kinesin protein that plays a critical role in cytokinesis. Previously, we and others have demonstrated the oncogenic role of KIF20B in several cancers; however, the exact mechanisms underlying its tumorigenic effects remain unclear. Herein, we showed overexpression of KIF20B in human hepatocellular carcinoma (HCC) and reported a negative correlation between KIF20B level and prognosis of patients. Mechanistically, reducing KIF20B blockades mitotic exit of HCC cells at telophase in a spindle assembly checkpoint independent way. Importantly, reducing KIF20B acts synergistically with three microtubule-associated agents (MTA) to p53-or p14ARF-dependently suppress p53-wt or p53-null HCC cells. In addition to taxol, reducing KIF20B also enhanced the toxicity of two chemotherapeutic drugs, hydroxycamptothecin and mitomycin C. In conclusion, we found a novel mechanism in that blocking cytokinesis by KIF20B inhibition increases the efficacy of MTA; our results thus suggested a dual-mitotic suppression approach against HCC by combining MTA with KIF20B inhibition, which simultaneously blocks mitosis at both metaphase and telophase.
| INTRODUCTION
Hepatocellular carcinoma causes 600 000 deaths annually. 1 As a result of the lack of effective drug therapy, HCC patients usually have a poor prognosis. Most of the chemotherapeutic drugs, such as taxol, epirubicin, cisplatin, 5-fluorouracil and etoposide, either individually or in combination, have relatively low efficacy in treating HCC. 2 Great efforts have been made to unveil the mechanisms underlying the insensitivity of HCC cells to chemotherapies, such as MTA. 3, 4 One main cause that confers MTA resistance to HCC cells is the mitotic checkpoint bypass. 5 For example, the regulation of SAC, which controls cell cycle progression during mitosis and synchronizes mitosis by attaching chromosomes to spindle microtubules, 6 is critical for taxol-mediated cell death. 7, 8 However, reduced or malfunctioned SAC is commonly seen in cancer cells, 9 and such SAC defects usually correlate with MTA resistance. 10 Therefore, new approaches targeting alternative checkpoints besides SAC would help treat MTA-resistant HCC.
Kinesin family member 20B (KIF20B, also known as MPHOSPH1)
belongs to the kinesin superfamily (KIF), which shares a highly conserved motor domain that enables its microtubule-dependent plusend motion ability through its ATPase activity. 11 KIF20B is a microtubule-associated protein specifically phosphorylated at M-phase and plays a critical role in cytokinesis. 12 In addition to its physiological roles in mitosis, KIF20B has also been found to play roles in solid tumors such as breast and bladder cancers. 13, 14 Recently, we also reported the oncogenic role of KIF20B in HCC. 15 However, the mechanism by which reducing KIF20B suppresses HCC remains unresolved.
Herein, we showed that reducing KIF20B suppresses HCC proliferation through blocking cytokinesis in a SAC-independent way. We designed and tested a dual-mitotic suppression strategy against HCC by combining MTA with KIF20B blockade. Synergistic antitumor effects were achieved through KIF20B reduction combined with multiple MTA in cultured HCC cells, suggesting the potential of this dual-mitotic suppression strategy against HCC, which simultaneously blockades metaphase and cytokinesis.
| MATERIALS AND METHODS

| Compounds
Microtubule-targeting agents taxol, epothilone B and vincristine, Aurora inhibitor VX-680, spindle assembly checkpoint inhibitor AZ3146, and cytokinesis inhibitor blebbistatin were from Sigma-Aldrich (St Louis, MO, USA). Hydroxycamptothecin and mitomycin C were from Selleck Chemicals (Houston, TX, USA). 
| Cell lines and tissue specimens
| Recombinant adenoviral vectors
Recombinant adenoviruses were generated by respective homologous recombination between the shuttle plasmids and the packaging plasmid pBHGE3 in HEK293 cells. Generation, identification, production, purification, and titration of the recombinant adenovirus were carried out as previously described.
18,19
| Lentiviral vectors
Stably expressing shKIF20B cell lines using the lentiviral system were constructed as previously reported. 16 
| Immunohistochemical staining
Paraffin-embedded tissue samples from patients were cut into 5-μm sections and placed on poly-lysine-coated slides. Samples were deparaffinized in xylene and rehydrated using a series of graded alcohol. Antigen retrieval was carried out by heat mediation in citrate buffer. Samples were blocked with 10% goat serum before incubation with primary antibody. Samples were incubated overnight using primary antibodies a humidified container at 4°C.
Immunohistochemical staining was carried out with a DAB Horseradish Peroxidase Color Development Kit (Beyotime Biotechnology, Shanghai, China) according to the manufacturer's instructions.
Intensity of staining was carried out and analyzed using Histoscore by two individuals through a double-blind procedure as reported. 20 
| Cell viability assays
MTT assays were carried out using standard procedures as previously reported. 21 For colony formation assays, cells were counted and seeded in six-well plates in growth medium containing 0.7% agar (2 mL/well) on top of a layer of growth medium containing 1.4% agar (1 mL/well). Growth medium (1 mL) with 10% FBS was added on top of the agar. The cell suspension was plated and cultured in a 37°C incubator for 20 days, then the colonies were fixed with 4% paraformaldehyde, stained with 0.005% (w/v) crystal violet in 25%
(v/v) methanol, and the colonies were then pictured and counted. 
| Western blot
Western blots were carried out with standard procedures as previously reported. 23 The following primary antibodies were used: rabbit 
| In vitro nuclei and microtubule staining
Nuclei and microtubule staining were carried out as previously reported. 24 Cells were seeded on glass coverslips, and 24 hours later they were infected with adenovirus at MOI of 1. Cells were then fixed with 4% paraformaldehyde, and costained with Phalloidin Alexa Fluor 555 (Molecular Probes, Eugene, OR, USA) and DAPI (Sigma-Aldrich). Cells were observed and pictured using a Leica TCS SP2 confocal microscope (Leica Microsystems, Wetzlar, Germany).
| Statistics
All data are expressed as the mean ± SD and were analyzed using independent sample t tests and one-way analyses of variance (ANOVA) using SPSS Base 10.0. Results were considered statistically significant when P < .05.
| RESULTS
| Kinesin family member 20B overexpression is correlated with poor prognosis in HCC
Upregulated KIF20B has been reported in some solid tumors, such as breast and bladder cancers. 13 Here, we observed a significant upregulation of KIF20B in HCC tissues (n = 50) compared with adjacent (n = 36) or non-tumor (n = 14) tissues ( Figure 1A ,B). We further analyzed the data of 336 HCC and 42 non-tumor patients available in The Cancer Genome Atlas (TCGA) database to investigate whether KIF20B expression correlates with HCC prognosis. Consistent with the IHC results, the mRNA levels of KIF20B were much higher in HCC tissues compared with normal tissues ( Figure 1C ).
Importantly, HCC patients with higher than median KIF20B expression showed significantly shorter overall (P = .036, left panel, Fig- ure 1D) and disease-free survival duration (P = .022, right panel, Figure 1D ), especially in the early period, which has a higher confidence level compared to the late stage. Together, these results suggest upregulated KIF20B in HCC tissues, and its expression level is negatively correlated with the prognosis of patients.
| Reducing KIF20B sensitizes HCC cells to taxol
Evidence has suggested that some KIF proteins are correlated with taxol resistance of cancer cells. 25 To fully address whether reducing KIF20B increases the taxol sensitivity of HCC cells, we applied Ad- 
| Reducing KIF20B suppresses mitosis of HCC cells at telophase
At metaphase/anaphase transition, SAC activation is essential for the efficacy of taxol; 7 however, some cancer cells can bypass its surveillance to escape from taxol inhibition. 9 To address whether shKIF20B
suppresses HCC cells in a SAC-dependent way, a SAC inhibitor AZ3146 was applied. 26 As expected, AZ3146 significantly attenuated the cytotoxicity of taxol to HepG2 cells ( Figure 3A ). In contrast, the viability of cells receiving Ad-shKIF20B or Ad-shKIF20B/taxol combination was unaffected by AZ3146 treatment ( Figure 3A) , indicating that the suppressive function of shKIF20B is independent of SAC activation.
As SAC does not affect shKIF20B-induced mitotic and proliferation inhibition, and KIF20B plays a critical role in cytokinesis, indicator. 27 Significantly delayed mitotic exit of cells receiving shKIF20B was observed as shown by decreased p-H3 levels (12 vs 5 hours, Figure 3B ), suggesting a prolonged mitotic arrest induced by KIF20B knockdown. In addition, consistent with a previous report, 22 VX-680 re-administration at 3 hours released cells from mitotic arrest (shown by decreased p-H3 levels, Figure 3C ). Next, confocal microscopy was applied to examine the cell phase. At 4 hours after release from synchronization, shKIF20B induced a significant increase in the number of cells arrested at telophase (shown as cytokinesis, yellow arrows, Figure 3D ,E); this result was similar to the cells receiving blebbistatin, an agent that induces mitotic defects of cytokinesis ( Figure 3D,E) . 28 In contrast, taxol and epothilone B (epo B), the latter is an MTA in clinical trials for breast and ovarian cancers, 29 mainly caused arrest at pro-meta- blockaded mitotic exit at telophase, whereas taxol/epo B mainly suppressed mitosis at metaphase.
| Reduction of KIF20B sensitizes HCC cells to taxol through mitotic arrest and p53/p14ARF
Tumor suppressor p53 plays a critical role in the development of drug resistance in cancer cells, and its accumulation during mitotic arrest triggers apoptosis following mitotic slippage. 30 To explore whether the reduced cell viability by shKIF20B/taxol depends on the p53 pathway in p53-wt cells, a p53-specific inhibitor pifithrin-α was used. 31 Levels of p53 and its downstream cell cycle inhibitor p21
were upregulated by shKIF20B, whereas pifithrin-α reversed these upregulations ( Figure 4A ). MTT assays indicated that pifithrin-α significantly attenuated the toxicity of shKIF20B/taxol combined treatment on HepG2 cells ( Figure 4B ). Moreover, VX-680 treatment, which releases cells from mitotic arrest ( Figure 3C ,E), also significantly attenuated the inhibitory effects of shKIF20B/taxol on cell viability ( Figure 4B ). These results suggested that combined shKIF20B/taxol treatment suppressed cell growth in p53-wt HCC cells through a p53-and mitotic arrest-dependent method.
In p53-null and p53-mutated cancer cells, p14ARF may partially substitute for p53 in inhibiting the proliferation; 32 we thus hypothesized that reduction of cell viability by shKIF20B in p53-null cells may depend on p14ARF. To test this possibility, we knocked down p14ARF
in Hep3B cells using a shp14 plasmid ( Figure 4C ). As expected, the levels of p14ARF and p21 were increased by Ad-shKIF20B infection and decreased after knockdown of p14ARF by shp14 ( Figure 4C ).
MTT assays showed that p14ARF knockdown attenuated the AdshKIF20B/taxol combination-induced viability suppression ( Figure 4D ), suggesting that shKIF20B-enhanced taxol efficacy may depend on p14ARF. Similarly, in Hep3B cells, release from mitotic arrest also attenuated the combined shKIF20B/taxol treatment-induced proliferation inhibition, showing a mitotic arrest-dependent mechanism. Taxol and epo B suppress mitosis at metaphase ( Figure 3D ,E), whereas shKIF20B induces cytokinesis inhibition at telophase. We therefore hypothesized that a strategy simultaneously blocking metaphase and telophase of mitosis may achieve better outcomes.
Besides taxol, we studied two additional common MTA (epo B and vincristine) on HCC cell lines. Cell viability assays showed that shKIF20B increased the toxicity of epo B to all three cell lines (Figure 5A) , and Ad-shKIF20B acted synergistically with epo B to suppress proliferation ( Figure 5B ). Similarly, shKIF20B significantly enhanced the efficacy of vincristine in synergy with all HCC cells ( Figure 5C,D) . Together, these results indicated that shKIF20B and MTA synergistically inhibit proliferation of HCC cells.
| Reducing KIF20B sensitizes HCC cells to two chemotherapeutic agents
In the clinic, transarterial chemoembolization (TACE) is a first-line therapeutic option for HCC treatment, and multiple chemotherapeutic drugs have been used in TACE, such as mitomycin and camptothecin. 33 To determine whether reducing KIF20B sensitizes HCC Figure 6A ). Furthermore, by using a lentiviral vector system that we previously used, 16 we constructed two HCC cell lines that stably expressed shKIF20B (HepG2-KIF20BKD and Hep3B-KIF20BKD, Figure 6B ). Both KIF20B knockdown cell lines were much more sensitive to hydroxycamptothecin or mitomycin C than the control cells ( Figure 6C ), suggesting that reducing KIF20B also elevates the cytotoxicity of these TACE chemotherapeutic agents.
| DISCUSSION
Many studies have indicated SAC as a critical checkpoint that strictly surveils the process of mitosis and controls the metaphase/ anaphase transition. 34, 35 Including taxol, many MTAs cause cell death via activating SAC, which induces mitotic arrest and subsequent apoptosis ( Figure 7 ). 36 However, some cancer cells can bypass its surveillance by reducing or inactivating SAC and therefore escape from mitotic arrest to become insensitive to SAC-activating MTA. In addition to KIF, some agents with cytokinesis inhibition ability, such as mulberry water extract, have been shown to increase the efficacy of taxol to bladder cancer with a synergistic effect. 40 However, it is not clear whether a cytokinesis defect is responsible for the synergistic antitumor effect. Herein, we demonstrate that KIF20B reduction increases HCC sensitivity to multiple MTA by blocking cytokinesis. Moreover, our work also raises the possibility that besides KIF20B, additional cytokinesis-associated proteins may also serve as potential therapeutic targets. Future studies on the roles and molecular mechanisms of these molecules in MTA-resistant cancers will be interesting. acute leukemia and colon cancer treatments. 41, 42 As such regulators are activated in a broad range of cancers and control different stages of cell cycle, we speculate that triggering different checkpoints, which simultaneously blockades multiple cell cycle events, may achieve potent efficacy against MTA-resistant cancers.
In the present study, we tested the combinatorial HCC therapy as proof of concept, and it will be interesting to apply this dual suppressive strategy to other MTA-resistant cancers, such as colon and breast cancers. 
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